June 19, 2019
CARsgen Therapeutics’ leading candidate gets FDA IND clearance
One of CARsgen Therapeutics’ leading drug candidates, CT053 fully human BCMA (B-Cell Maturation Antigen)-CAR-T cell for the treatment of patients suffering from relapsed/refractory multiple myeloma (rrMM), has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration (FDA).